Drug Profile
Research programme: myocardial infarction therapy - ITL Pharma
Alternative Names: CardioSafeLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator ITL Pharma
- Class Cardiovascular therapies
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Myocardial-infarction in USA (Tablet)
- 21 Feb 2017 Research programme: myocardial infarction therapy - ITL Pharma is available for licensing as of 21 Feb 2017. http://www.itlpharmaceuticals.com/investors.html
- 21 Feb 2017 Early research in Myocardial infarction in USA (unspecified route)